A Randomized, Placebo-Controlled, Multiple Ascending Dose Study Assessing Safety, Tolerability, Pharmacodynamics, Efficacy, and Pharmacokinetics of DYNE-101 Administered to Participants With Myotonic Dystrophy Type 1
Latest Information Update: 23 May 2024
At a glance
- Drugs DYNE-101 (Primary)
- Indications Myotonic dystrophy
- Focus Adverse reactions; First in man; Registrational
- Acronyms ACHIEVE
- Sponsors Dyne Therapeutics
- 20 May 2024 According to a Dyne Therapeutics media release, the comapny plans to continue to engage with global regulators this year on ACHIEVE and DELIVER, and anticipates providing an update on the path to registration for both DYNE-101 and DYNE-251 by the end of 2024.
- 20 May 2024 Results presented in a Dyne Therapeutics Media Release.
- 19 May 2024 According to a Dyne Therapeutics media release, announced it now plans to report new efficacy and safety data from its Phase 1/2 ACHIEVE and DELIVER clinical trials on May 20, 2024, and to host a virtual event at 8:00 a.m. ET.